107 results
SC 14D9/A
EX-99
CBAY
Cymabay Therapeutics Inc
28 Feb 24
Tender offer solicitation (amended)
5:01pm
of seladelpar in patients with PBC intended to collect additional long-term safety and efficacy data to further support registration. There are now over 300
SC TO-T
EX-99
CBAY
Cymabay Therapeutics Inc
23 Feb 24
Third party tender offer statement
6:09am
events or safety observations or reports of new side effects, adverse events or safety observations, and other related matters) (except … healthcare company, building out the Legal, Ethics and Compliance, and Environmental Health and Safety organizations following the company’s separation from
SC TO-C
EX-99.3
CBAY
Cymabay Therapeutics Inc
12 Feb 24
Information about tender offer
4:14pm
, safety and tolerability profiles were comparable between treatment and placebo arms.
Summary Table of Key Results from Phase 3 Trials:
RESPONSE (N
8-K
EX-2.1
9svha0juv pla
12 Feb 24
Entry into a Material Definitive Agreement
8:42am
SC TO-C
EX-2.1
bf84s7rhfhtu
12 Feb 24
Information about tender offer
8:39am
8-K
EX-1.1
1r264k qyuwr5o7r6y0
12 Sep 23
Other Events
4:05pm
424B5
9x15 tckril48yzuj
12 Sep 23
Prospectus supplement for primary offering
4:02pm
424B5
hp5utfp1b6d
11 Sep 23
Prospectus supplement for primary offering
6:19am
8-K
xk5ld
11 Sep 23
Other Events
6:07am